A Phase 2/3 interventional study of Eculizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 35 sites in 7 countries. Per ClinicalTrials.gov, last updated 2024-09-25.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is the only one that started in 2020, is one of 3 in phase 2/3, and was the 4th registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Alexion Pharmaceuticals, Inc. · Sites in United States, Argentina, Canada and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8
First in 2014; this study’s year is marked. 1 started in 2020.
This study's enrollment of 5 is below the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.
Median enrollment 40 across the 8 interventional studies, 75 across the 3 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Neuromyelitis Optica by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06724809Phase 3Alexion Pharmaceuticals, Inc.Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Neuromyelitis Optica by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to \< 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive open-label eculizumab by intravenous infusion during the Primary Treatment Period, starting on Day 1 and for a total of 52/53 weeks. The dosing regimen will be based on the participant's body weight. As body weight changes during the study, the participant's weight cohort and dose may change accordingly. After completing the 52/53-week Primary Treatment Period, participants may continue receiving eculizumab in the Extension Treatment Period for 104 weeks.
Drug: Eculizumab
Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
Also known as: Soliris
Change Between the Baseline Annualized Relapse Rate (ARR) and the On-Trial ARR at Week 52/53
ARR was calculated as the number of relapses for each participant divided by the number of years of treatment for that participant. Baseline ARR was based on 24 months prior to screening.
Time frame: Baseline, Week 52/53
Time to First On-trial Relapse
Time to First Relapse was defined as beginning at the time the participant's first dose of eculizumab was administered until the participant's first on-trial relapse was reported by the Investigator. Participants who did not experience an on-trial relapse were censored at the end of the study period.
Time frame: Baseline up to Week 52/53
Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 52/53
Disease-related disability was measured by the EDSS. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement.
Time frame: Baseline, Week 52/53
Change From Baseline in the Hauser Ambulation Index (HAI) Score at Week 52/53
The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranged from 0 to 9, with 0 being the best score (asymptomatic; fully ambulatory with no assistance) and 9 being the worst (restricted to wheel chair; unable to transfer self independently). A decrease in score indicates improvement.
Time frame: Baseline, Weeks 52/53
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Score at Week 52/53
PedsQL included a child self-report for participants 5 to 18 years with a 23-item PedsQL Generic Core Scales report. The PedsQL Generic Core Scales report included 4 scales, physical functioning, emotional functioning, social functioning, and school functioning. Each item used a 5-point rating scale (from 0=never to 4=almost always). Items are reverse scored and linearly transformed to a 0 (almost always) -100 (never) scale. All summary/total scores were mean of specific items where higher score indicated better HRQoL.
Time frame: Baseline, Weeks 52/53
Number of Participants With Shift From Baseline in Visual Acuity (VA)
The Snellen chart was used to assess VA. The Snellen chart quantifies ability to read letters of varying sizes at a fixed distance in relation to the distance at which a participant with normal vision could read the same letters. The test was performed at a standard distance, typically 6 meters or 20 feet. The Snellen chart is typically recorded as acuity ratio distance (6 meters or 20 feet), so for normal VA it would be recorded as 20/20 or 6/6. Visual acuity was summarized according to the eye with greater worsening at the end of primary treatment period (Week 52/53). Data are presented for number of participants with a shift from baseline in VA presented per the different levels of acuity ratio distance. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group. Visual Acuity data are only reported for the categories with available data at Baseline and Week 52/53.
Time frame: Baseline, Week 52/53
Number of Participants With Shift From Baseline in Confrontational Visual Fields (VF)
Confrontational visual fields were summarized according to the number of quadrants with deficits across both eyes. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.
Time frame: Baseline, Weeks 52/53
Number of Participants With Shift From Baseline in Color Vision
Color vision was evaluated as the shift from baseline and described for participants with normal color vision at baseline in at least one eye. Participants with 13 or less correctly identified Ishihara plates were considered as having abnormal color vision, participants with 14 or more correctly identified plates were considered as having normal color vision. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.
Time frame: Baseline, Weeks 52/53
Serum Eculizumab Concentration at Week 52
Time frame: Week 52
Change From Baseline in Serum Free Complement Protein 5 (C5) Concentrations at Week 52
Time frame: Baseline, Week 52
| Milestone | Eculizumab |
|---|---|
| Started | 5 |
| Received at least 1 dose of study drug | 5 |
| Number of participants who received study drug during the induction period | 5 |
| Number of participants who received study drug during the maintenance period | 5 |
| Completed | 0 |
| Not completed | 5 |
| Withdrew: Other than specified | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Adverse event | 1 |
ARR was calculated as the number of relapses for each participant divided by the number of years of treatment for that participant. Baseline ARR was based on 24 months prior to screening.
| relapses per participant per year | Eculizumab |
|---|---|
| Change Between the Baseline Annualized Relapse Rate (ARR) and the On-Trial ARR at Week 52/53 | -3.01 ± 2.504 |
Time to First Relapse was defined as beginning at the time the participant's first dose of eculizumab was administered until the participant's first on-trial relapse was reported by the Investigator. Participants who did not experience an on-trial relapse were censored at the end of the study period.
No measurements were reported for this outcome.
Disease-related disability was measured by the EDSS. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. A decrease in score indicates improvement.
| score on a scale | Eculizumab |
|---|---|
| Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Week 52/53 | -0.75 ± 1.708 |
The HAI evaluates gait and was used to assess the time and effort used by the participant to walk 25 feet (8 meters). The scale ranged from 0 to 9, with 0 being the best score (asymptomatic; fully ambulatory with no assistance) and 9 being the worst (restricted to wheel chair; unable to transfer self independently). A decrease in score indicates improvement.
| score on a scale | Eculizumab |
|---|---|
| Change From Baseline in the Hauser Ambulation Index (HAI) Score at Week 52/53 | 0.0 ± 0.00 |
PedsQL included a child self-report for participants 5 to 18 years with a 23-item PedsQL Generic Core Scales report. The PedsQL Generic Core Scales report included 4 scales, physical functioning, emotional functioning, social functioning, and school functioning. Each item used a 5-point rating scale (from 0=never to 4=almost always). Items are reverse scored and linearly transformed to a 0 (almost always) -100 (never) scale. All summary/total scores were mean of specific items where higher score indicated better HRQoL.
| score on a scale | Eculizumab |
|---|---|
| Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Score at Week 52/53 | -5.01 ± 10.401 |
The Snellen chart was used to assess VA. The Snellen chart quantifies ability to read letters of varying sizes at a fixed distance in relation to the distance at which a participant with normal vision could read the same letters. The test was performed at a standard distance, typically 6 meters or 20 feet. The Snellen chart is typically recorded as acuity ratio distance (6 meters or 20 feet), so for normal VA it would be recorded as 20/20 or 6/6. Visual acuity was summarized according to the eye with greater worsening at the end of primary treatment period (Week 52/53). Data are presented for number of participants with a shift from baseline in VA presented per the different levels of acuity ratio distance. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group. Visual Acuity data are only reported for the categories with available data at Baseline and Week 52/53.
| Participants | Eculizumab |
|---|---|
| Shift from VA 20/20-20/29 to VA 20/20-20/29 | 3 |
| Shift from VA 20/30-20/59 to VA 20/20-20/29 | 1 |
Confrontational visual fields were summarized according to the number of quadrants with deficits across both eyes. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.
| Participants | Eculizumab |
|---|---|
| 0 to 0 | 2 |
| 2 to 0 | 1 |
Color vision was evaluated as the shift from baseline and described for participants with normal color vision at baseline in at least one eye. Participants with 13 or less correctly identified Ishihara plates were considered as having abnormal color vision, participants with 14 or more correctly identified plates were considered as having normal color vision. Baseline was defined as the last available assessment prior to the first IP study drug infusion for all participants regardless of treatment group.
| Participants | Eculizumab |
|---|---|
| No Change from Normal | 4 |
| Worsened from Baseline | 0 |
| micrograms/milliliters | Eculizumab |
|---|---|
| Pre-dose: 5-90 Minutes | 460.7 ± 65.04 |
| Post-dose: 60 minutes | 971.3 ± 198.04 |
| micrograms/milliliters | Eculizumab |
|---|---|
| Baseline | 166.67 ± 50.203 |
| Change from Baseline at Week 52 | -166.64 ± 50.194 |
Collected over Baseline up to Week 53. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Event | Eculizumab |
|---|---|
| Liver function test increasedInvestigations | 1/5 |
| Encephalitis meningococcalInfections and infestations | 1/5 |
| Event | Eculizumab |
|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/5 |
| AmenorrhoeaReproductive system and breast disorders | 1/4 |
| Abdominal pain lowerGastrointestinal disorders | 1/5 |
| Bowel movement irregularityGastrointestinal disorders | 1/5 |
| ConstipationGastrointestinal disorders | 1/5 |
| Dental cariesGastrointestinal disorders | 1/5 |
| NauseaGastrointestinal disorders | 1/5 |
| VomitingGastrointestinal disorders | 1/5 |
| Feeling abnormalGeneral disorders | 1/5 |
| PyrexiaGeneral disorders | 1/5 |
Safety Set included all participants who received at least 1 dose of eculizumab.
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 12.0 ± 4.36 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 4 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 3 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Jul 2023, 42 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →